Page 5 - Pharmaceutical Firms

Research-linked incentive scheme in works for pharmaceutical industry

15% turnover investment in research could make companies eligible for the scheme

Natl Pharma Pricing Authority fixes retail prices of 84 drug formulations

Drug pricing regulator NPPA has fixed the retail prices for 84 drug formulations, including those used for treatment of diabetes, headache and high blood pressure. The National Pharmaceutical Pricing Authority (NPPA) has also fixed the prices of formulations indicated to reduce increased cholesterol and triglycerides levels, among others. In exercise of the powers conferred by the Drugs (Prices Control) Order, 2013, the NPPA has fixed the retail prices of the medications, the regulator said in a notification. As per the order, a single tablet of Voglibose and (SR) Metformin Hydrochloride will cost Rs 10.47, excluding GST. Similarly, the price of Paracetamol and Caffeine has been fixed at Rs 2.88 per tablet. Besides, the price of one Rosuvastatin Aspirin and Clopidogrel capsule has been fixed at Rs 13.91. In a separate notification, NPPA said it has extended the revised ceiling price of liquid medical oxygen and oxygen inhalation (medicinal gas) till September 30 this year. The NP

Pharma company Innova Captab files draft papers with Sebi for IPO funding

Pharmaceutical company Innova Captab Ltd has filed preliminary papers with capital markets regulator Sebi to raise funds through an initial public offering (IPO). The proposed IPO comprises fresh issuance of equity shares worth Rs 400 crore and an offer for sale (OFS) of 96 lakh equity shares by promoters and other shareholders, according to the draft red herring prospectus (DRHP). As part of the OFS, Manoj Kumar Lohariwala, Vinay Kumar Lohariwala and Gian Parkash Aggarwal will sell 32 lakh shares each. At present, promoters -- Manoj and Vinay -- hold 39.66 per cent and 30.08 per cent stake, respectively, in the company, while Gian owns a 30.23 per cent holding in the pharma firm. Besides, the company may consider pre-IPO placement of equity shares aggregating up to Rs 80 crore. If such a placement is undertaken, the size of the fresh issue will be reduced. Of the Rs 400 crore proposed to be raised through fresh issuance of equity shares, Rs 180.5 crore will be used for payment of

India's first indigenous mRNA vaccine likely to be available soon

The Subject Expert Committee (SEC) has recommended granting the Emergency Use Authorisation (EUA) to the country's first mRNA-based Covid-19 vaccine in a meeting held on Friday

Cipla to invest Rs 26 cr in digital tech co GoApptiv to raise stake to 22%

Pharma company Cipla has agreed to acquire an additional stake for nearly Rs 26 crore in digital tech company GoApptiv Private to raise its shareholding to 22.02 per cent, the company said on Monday. The investment will be made in equity shares and Compulsorily Convertible Preference Shares and is likely to be completed within 30 days or such other date mutually agreed between the parties, Cipla said in a regulatory filing. Cipla's earlier investment in GoApptiv in June 2020 has yielded growth and expanded Cipla's channel reach across lower tier towns in India. "This investment will further strengthen our partnership with GoApptiv enabling wider patient reach with affordable and quality drugs and end-to-end brand marketing and channel engagement across tier 2-6 towns in India. 'Caring for Life' is at the heart of what we do and will guide us towards making such strategic investments to help make a difference in the lives of our patients," Umang Vohra, MD and Global CEO, Cipla Limite

Dr Reddy's Laboratories eyes place among top five domestic pharma players

The US would continue to remain an important geography, but the firm says it hopes to double its revenues from China and grow revenues five-fold in Brazil in the next five years

Dr Reddy's acquire Eton Pharma's injectable products for $50 million

Under the terms of the agreement, Dr Reddy's acquired the Eton portfolio for an upfront payment of approximately USD 5 million in cash, besides contingent payments of up to USD 45 million

CBI arrests Jt Drug Controller, Biocon Biologics execs over fishy approvals

All five apprehended will be presented in court on Tuesday afternoon, agency to seek police custody

Zydus Lifesciences' Rs 750 cr-share buyback open between June 23-July 6

The drug firm, earlier known as Cadila Healthcare, has fixed July 15, 2022 as the last date for the settlement of bids on stock exchanges which may even happen early, as per a regulatory filing.

Near-term growth issues and cost pressure could impact Aurobindo Pharma

While valuations are now attractive, product approvals and progress on the injectable guidance are among key long-term term triggers

WEF 2022: Pfizer commits medicines, vaccines to 45 lower-income countries

World Economic Forum (WEF) 2022: The initiative by Pfizer was launched at the World Economic Forum Annual Meeting in Davos 2022

Bayer CropScience Q4 net profit surges over two-fold; revenue rises 31%

In the fourth quarter of 2021-22, the company's revenue from operations witnessed a growth of 31.29 per cent to Rs 963.3 crore compared to Rs 733.7 crore in corresponding quarter of the previous year

Ipca Labs Q4 net profit declines 19% at Rs 130 crore on higher expenses

The company had posted a consolidated net profit after tax of Rs 161.34 crore in the same quarter previous fiscal, Ipca Laboratories said in a regulatory filing

Launches, base biz expansion tonic for Dr Reddy's double-digit growth

While the company's bottom line grew 10.5% annually over the 2016-17 through 2021-22 (FY22) period, it is expected to register thrice that growth rate over next two years, observes ICICI Securities

Zydus Lifesciences Q4 profit dips 41% to Rs 397 cr due to higher expenses

The company had posted a consolidated net profit of Rs 679 crore in the same quarter of previous fiscal year, Zydus Lifesciences said in a regulatory filing.

Dr Reddy's Labs Q4 PAT falls 76% on pricing pressure, low export benefit

Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review

Paradeep Phosphates IPO gets 29% subscription; retail portion booked 57%

The initial public offer of Paradeep Phosphates was subscribed 29 per cent on the first day of subscription on Tuesday. The IPO received bids for 7,86,87,000 shares against 26,86,76,858 shares on offer, according to data available with NSE. The category for Retail Individual Investors (RIIs) was subscribed 57 per cent and the portion for non-institutional investors attracted 6 per cent subscription. The Initial Public Offer (IPO) has a fresh issue of equity shares aggregating to Rs 1,004 crore and an offer for sale of up to 11,85,07,493 equity shares. As part of the OFS, Zuari Maroc Phosphates Pvt Ltd (ZMPPL) will offload 60,18,493 equity shares and the government of India will sell up to 11,24,89,000 equity shares. The government will be offloading its entire 19.55 per cent stake in the company. Currently, ZMPPL holds 80.45 per cent stake and the government of India owns the rest 19.55 per cent stake in the company. The price range for the offer is at Rs 39-42 per share. On Fr

Biological E plans to ramp up non-vaccines business in next three years

The privately held company has a turnover of about Rs 1,000 crore, of which close to 70-80 per cent come from the vaccines business now

Strong chemicals business outlook likely to support the SRF stock

This could aid overall profitability, even though other segments may see margin moderation

Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483

Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days